Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study

H. Horinouchi; J.W. Goldman; B.C. Cho; P. Tomasini; M. Dunbar; D. Hoffman; A. Parikh; V. Blot; D.R. Camidge

doi:10.1016/j.annonc.2022.10.424

YUHSpace

BROWSE

0 172

Cited 0 times in

Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study

Authors: H. Horinouchi ; J.W. Goldman ; B.C. Cho ; P. Tomasini ; M. Dunbar ; D. Hoffman ; A. Parikh ; V. Blot ; D.R. Camidge

Citation: ANNALS OF ONCOLOGY, Vol.33(Suppl 9) : S1592, 2022-11

Journal Title: ANNALS OF ONCOLOGY

ISSN: 0923-7534

Issue Date: 2022-11

Full Text: https://www.sciencedirect.com/science/article/pii/S0923753422046154

DOI: 10.1016/j.annonc.2022.10.424

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/194753

사서에게 알리기

Show full item record Find it @ YMLIB

License

YUHSpace: Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study

YUHSpace

BROWSE

Browse

Links